Mark J. Rosenblum - 31 Aug 2026 Form 4 Insider Report for Decoy Therapeutics Inc. (DCOY)

Reporting relationship: Chief Financial Officer
Issuer ticker: DCOY
Reported as of: 31 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Sep 2026, 17:48:11 UTC
Prior SEC filing: 20 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/Mark Rosenblum, as Attorney -in-Fact

Key filing fact

Mark J. Rosenblum filed Form 4 for Decoy Therapeutics Inc. (DCOY) on 02 Sep 2026.

Key facts

This page summarizes Mark J. Rosenblum's Form 4 filing for Decoy Therapeutics Inc. (DCOY).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Sep 2026, 17:48.

Change

Previous filing in this sequence was filed on 20 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001329154 Primary reporting owner

Rosenblum Mark J

Relationship: Chief Financial Officer
Address: 2450 HOLCOMBE BLVD STE X, HOUSTON
Signature: /s/Mark Rosenblum, as Attorney -in-Fact
Signature date: 02 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DCOY transaction

Common Stock

Award

Transaction value
Shares: +9,682
Change %: +576%
Price: $0.000000^*
Shares after: 11,363
Date: 31 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.

Footnote F2

Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.